Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CD19-depleted hematopoietic progenitor cell graft
- Development stage
- Unknown
- Lead developer
- St. Jude Children's Research Hospital
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
A specialized cellular therapy product developed by St. Jude Children's Research Hospital for use in allogeneic hematopoietic cell transplantation (HCT). The product consists of donor-derived hematopoietic progenitor cells that have undergone ex vivo depletion of CD19+ B-lymphocytes, typically using the CliniMACS magnetic cell separation system. This depletion is performed to minimize the risk of post-transplant lymphoproliferative disorder (PTLD) caused by Epstein-Barr virus (EBV) reactivation in the donor B-cells. In the context of haploidentical HCT for pediatric patients with high-risk hematologic malignancies (such as ALL and AML), this CD19-depleted graft is often administered alongside TCRαβ-depleted cells to reduce the incidence of graft-versus-host disease (GVHD) while maintaining a potent graft-versus-leukemia effect through preserved NK cells and γδ T-cells.
- Other names
- CD19-depleted graftCD-19-depleted graftCD 19-depleted graftCD19+ depleted progenitor cellsCD19+ depleted hematopoietic stem cells
Beyond the preview
Go deeper on CD19-depleted hematopoietic progenitor cell graft.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CD19-depleted hematopoietic progenitor cell graft.